Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial.
Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Wang Y, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E J, Ying X, Yao C, Shen L, Ji J.
Lancet Oncol. 2025 Mar;26(3):312-319. doi: 10.1016/S1470-2045(24)00676-4. Epub 2025 Feb 11.
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group.
Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.
Sahin U, Schuler M, Richly H, Bauer S, Krilova A, Dechow T, Jerling M, Utsch M, Rohde C, Dhaene K, Huber C, Türeci Ö.
Eur J Cancer. 2018 Sep;100:17-26. doi: 10.1016/j.ejca.2018.05.007. Epub 2018 Jun 21.
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K.
Nat Rev Clin Oncol. 2021 Aug;18(8):473-487. doi: 10.1038/s41571-021-00492-2. Epub 2021 Mar 31.
The Landscape and Prognosis of Microsatellite Stable (MSS) Esophageal, Gastro-Esophageal Junction and Gastric Adenocarcinomas with High Tumor Mutation Burden (TMB).
Voutsadakis IA.
Cancer Invest. 2024 Sep;42(8):697-709. doi: 10.1080/07357907.2024.2388107. Epub 2024 Aug 8.
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M.
Ann Oncol. 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199.
"Gastro-Esophageal junction GIST".
Bhange SA, Sathe SM, Gala AP, Bhansali MS.
Indian J Cancer. 2015 Oct-Dec;52(4):510-2. doi: 10.4103/0019-509X.178390.
The complexity of cancer origins at the gastro-oesophageal junction.
Bornschein J, Quante M, Jansen M.
Best Pract Res Clin Gastroenterol. 2021 Mar-Apr;50-51:101729. doi: 10.1016/j.bpg.2021.101729. Epub 2021 Feb 14.
Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction.
Hulshof MC, van Laarhoven HW.
Best Pract Res Clin Gastroenterol. 2016 Aug;30(4):551-63. doi: 10.1016/j.bpg.2016.06.002. Epub 2016 Jun 25.
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
Khan U, Shah MA.
Expert Opin Biol Ther. 2019 Nov;19(11):1135-1141. doi: 10.1080/14712598.2019.1656715. Epub 2019 Aug 27.
